Skip to content
10-Q

Quarterly Report

NEUROCRINE BIOSCIENCES INC NBIX

0000914475-26-000026

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 100.55M sh
Shares Diluted Q1 2026 · Mar 31, 2026 103.4M sh
Shares Diluted Q1 2026 · Mar 31, 2025 102.5M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $54M
Stock Repurchased Q1 2026 · Mar 31, 2025 $150M
Capex Q1 2026 · Mar 31, 2026 $9.1M
Capex Q1 2026 · Mar 31, 2025 $10.7M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $145.8M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $64.8M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $266.5M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $713M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $194.1M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.41B
Stockholders Equity Q1 2026 · Dec 31, 2025 $3.25B
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.54B
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.59B
Current Liabilities Q1 2026 · Mar 31, 2026 $831.7M
Current Liabilities Q1 2026 · Dec 31, 2025 $743.4M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.5B
Total Liabilities Q1 2026 · Dec 31, 2025 $1.38B
Current Assets Q1 2026 · Mar 31, 2026 $2.44B
Current Assets Q1 2026 · Dec 31, 2025 $2.52B
Total Assets Q1 2026 · Mar 31, 2026 $4.91B
Total Assets Q1 2026 · Dec 31, 2025 $4.63B
Eps Diluted Q1 2026 · Mar 31, 2026 $1.91
Eps Diluted Q1 2026 · Mar 31, 2025 $0.08
Eps Basic Q1 2026 · Mar 31, 2026 $1.97
Eps Basic Q1 2026 · Mar 31, 2025 $0.08
Sga Expense Q1 2026 · Mar 31, 2026 $318.5M
Sga Expense Q1 2026 · Mar 31, 2025 $276.5M
Net Income Q1 2026 · Mar 31, 2026 $197.9M
Net Income Q1 2026 · Mar 31, 2025 $7.9M
Operating Income Q1 2026 · Mar 31, 2026 $193.4M
Operating Income Q1 2026 · Mar 31, 2025 $23.6M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $13.8M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $9.2M
Revenue Q1 2026 · Mar 31, 2026 $814.5M
Revenue Q1 2026 · Mar 31, 2025 $572.6M